---
document_datetime: 2025-05-05 15:11:08
document_pages: 20
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/deltyba-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: deltyba-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 11.2896779
conversion_datetime: 2025-12-22 07:43:00.549192
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Deltyba

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                                                                                    |
|----------------------|-----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0076               | Renewal of the marketing authorisation. | 30/01/2025                          | 25/04/2025                                  | SmPC, Annex II and PL            | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                     |                                                         |            |     | renewal of the conditional MA for Deltyba, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. SOB 002 has been revised, to specify that the use of delamanid should be investigated in different combination treatment regimens as per approved indication. Because the MAH has not been able to agree on terms that would allow for data sharing of the individual patient data (IPD) of the endTB study, the delamanid-specific analysis based on the CHMP agreed statistical analysis plan will not be possible as this was based on the availability of the IPD. Publicly available data will have to be used instead, both from the publication of the endTB study results and from the planned 2025 WHO update of the tuberculosis treatment guidelines. A critical discussion of the publicly available data is also required, including as possible an analysis based on the agreed delamanid-specific analysis plan and with an additional discussion when deviating from it. Finally, publicly available results from the BEAT-TB South-Africa clinical study conducted by Wits Health Consortium should be submitted and discussed. In this study the 6-month BDLLfxC regimen was investigated in place of 9-month or longer (> 18 months) regimens in patients with RR-TB. The due date of SOB 002 was also changed from Q2 2025 to Q3 2026, and it was specified that the MAH should   |
|---------------------|---------------------------------------------------------|------------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10213 /202404 | Periodic Safety Update EU Single assessment - delamanid | 28/11/2024 | n/a | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| IA/0077             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                    | 02/10/2024   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0075             | B.II.f.z - Stability of FP - Other variation                                                                                                                                                     | 16/08/2024   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| IB/0073             | B.II.c.z - Change in control of excipients in the Finished Product - Other variation                                                                                                             | 24/06/2024   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| PSUSA/10213 /202310 | Periodic Safety Update EU Single assessment - delamanid                                                                                                                                          | 16/05/2024   | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| R/0070              | Renewal of the marketing authorisation.                                                                                                                                                          | 14/12/2023   | 26/02/2024 | Annex II    | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Deltyba, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. The due date for the specific obligation (SOB 002) related to the submission of the results of the Evaluating Newly approved Drugs for multidrug-resistant TB (endTB) study has been postponed, from Q3 2024 to Q2 2025. |
| PSUSA/10213 /202304 | Periodic Safety Update EU Single assessment - delamanid                                                                                                                                          | 14/12/2023   | 22/02/2024 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10213/202304.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| IA/0071             | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) | 12/12/2023   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| II/0061   | Update of sections 4.2 and 4.4 of the SmPC in order to update the treatment duration based on final results from EU PASS (protocol no. 242-12-402), listed as a category 3 study in the RMP. This is a 'A Multicentre, EU-wide, Non-Interventional Post- Authorisation Study to Assess the Safety and Usage of Delamanid in Routine Medical Practice in Multidrug-Resistant Tuberculosis (MDR-TB) Patients'. This treatment registry was for monitoring and documenting Deltyba use in routine medical practice and aimed to assess compliance with the recommendations in the authorised product information when prescribed as part of an appropriate combination regimen (ACR) for the treatment of MDR-TB. The Package Leaflet is updated accordingly. Update of Annex II and the RMP to version 5.0 to remove the additional Risk Minimisation Measures (aRMMs). C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance   | 06/07/2023   | 22/02/2024   | SmPC, Annex II and PL   | SmPC new text Section 4.2 Treatment duration The total duration of treatment with delamanid is 24 weeks. Data on longer treatment duration is very limited. When treatment with delamanid is considered necessary beyond 24 weeks to obtain a curative treatment, a longer duration of therapy may be considered. Section 4.4 Deletion of the sentence: There are no data on treatment with delamanid for mor than 24 consecutive weeks (see section 4.2). For more information, please refer to the Summary of Product Characteristics.   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0068/G | This was an application for a group of variations. A.8 - Administrative change - Changes to date of the audit to verify GMP compliance of the manufacturer of AS A.8 - Administrative change - Changes to date of the audit to verify GMP compliance of the manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 04/07/2023   | n/a          |                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|                     | of AS                                                                                                                                                                                                                                                             |            |            |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0067             | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                         | 15/06/2023 | 22/02/2024 | SmPC     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| PSUSA/10213 /202210 | Periodic Safety Update EU Single assessment - delamanid                                                                                                                                                                                                           | 12/05/2023 | n/a        |          | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| R/0062              | Renewal of the marketing authorisation.                                                                                                                                                                                                                           | 26/01/2023 | 24/03/2023 | Annex II | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Deltyba, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. |
| IA/0066             | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                      | 08/03/2023 | n/a        |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| PSUSA/10213 /202204 | Periodic Safety Update EU Single assessment - delamanid                                                                                                                                                                                                           | 01/12/2022 | n/a        |          | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| IA/0064/G           | This was an application for a group of variations. B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size B.II.b.3.a - Change in the manufacturing process of | 22/11/2022 | n/a        |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|           | the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                             |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0063/G | This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                           | 03/11/2022 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| IB/0060   | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                    | 07/09/2022 | 24/03/2023 | SmPC        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| II/0053   | Update of section 4.8 of the SmPC in order to update the list of adverse drug reactions (ADRs table) following the development of an improved methodology to identify relevant ADRs likely attributable to delamanid. The section 4 of the Package Leaflet is updated accordingly. The RMP version 4.1 has also been submitted. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 01/09/2022 | 24/03/2023 | SmPC and PL | The MAH has proposed an update of section 4.8 of the SmPC, based on a statistical and medical judgement of ADRs seen in the two clinical trials 204 (phase 2) and 213 (phase 3) as well from all post-marketing sources. Some ADRs were removed due to insufficient supporting evidence to retain them, in addition there was an update of some of the ADR frequencies, grouping of terms and addition of hypothyroidism with a frequency 'common'. For more information, please refer to the Summary of Product Characteristics. |

<div style=\"page-break-after: always\"></div>

| IB/0058             | B.II.z - Quality change - Finished product - Other variation                                                                                                                                                                                                                                                                                                       | 18/07/2022   | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0057/G           | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process | 07/06/2022   | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| R/0052              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                            | 27/01/2022   | 22/03/2022 | SmPC, Annex II and PL | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Deltyba, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. |
| PSUSA/10213 /202104 | Periodic Safety Update EU Single assessment - delamanid                                                                                                                                                                                                                                                                                                            | 16/12/2021   | 16/02/2022 | SmPC and PL           | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10213/202104.                                                                                                                                                                                                                                                                                                                                        |
| IAIN/0056           | B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer                                                                                                                                                     | 01/02/2022   | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| IA/0055             | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                       | 04/01/2022   | n/a        |                                  |                                                                                                                 |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------|
| IB/0054/G           | This was an application for a group of variations. B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data) | 12/11/2021   | 16/02/2022 | SmPC, Annex II and PL            |                                                                                                                 |
| X/0046/G            | This was an application for a group of variations. Annex I_2.(d) Change or addition of a new pharmaceutical form C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                                                                                    | 22/07/2021   | 16/09/2021 | SmPC, Annex II, Labelling and PL |                                                                                                                 |
| PSUSA/10213 /202010 | Periodic Safety Update EU Single assessment - delamanid                                                                                                                                                                                                                                                                            | 10/06/2021   | n/a        |                                  | PRAC Recommendation - maintenance                                                                               |
| II/0048             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                  | 29/04/2021   | 16/09/2021 | SmPC and Annex II                |                                                                                                                 |
| R/0047              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                            | 25/02/2021   | 13/04/2021 | Annex II                         | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |            |                                  | having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Deltyba, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. The due date of SOB 002 in Annex II of the PI has been changed to Q1 2023.   |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0045 | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required                                                                                                                                                                                                                             | 09/04/2021 | 16/09/2021 | Annex II                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| IA/0050 | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 01/03/2021 | 16/09/2021 | Annex II and PL                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| II/0040 | Extension of indication to include adolescents and children with a body weight of at least 30 kg. As a consequence, sections 4.1, 4.2, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 3.2 of the RMP has also been submitted. Furthermore, the PI is brought in line with the latest QRD template version 10.1 and the Marketing Authorisation Holder (MAH) took the opportunity to make minor editorial changes. C.I.6.a - Change(s) to therapeutic indication(s) - | 17/09/2020 | 27/10/2020 | SmPC, Annex II, Labelling and PL | Please refer to Scientific Discussion 'Deltyba-H-C-002552- II-0040'                                                                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|                     | modification of an approved one                                                                                                                                                                                |            |            |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0044           | B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer | 25/06/2020 | n/a        |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| PSUSA/10213 /201910 | Periodic Safety Update EU Single assessment - delamanid                                                                                                                                                        | 14/05/2020 | n/a        |          | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| R/0041              | Renewal of the marketing authorisation.                                                                                                                                                                        | 27/02/2020 | 23/04/2020 | Annex II | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Deltyba, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. No changes to the Product Information (PI) are introduced with this renewal procedure. |
| IA/0042             | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)               | 03/12/2019 | n/a        |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| II/0037             | C.I.13 MIC report as amendment to CSR 242-09- 213.                                                                                                                                                             | 24/10/2019 | n/a        |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

|                     | elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                   |            |            |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0038             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                | 05/08/2019 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| PSUSA/10213 /201810 | Periodic Safety Update EU Single assessment - delamanid                                                                                                                                                                                      | 29/05/2019 | 25/07/2019 | SmPC and PL           | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10213/201810.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| IA/0039/G           | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites | 12/06/2019 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| R/0033              | Renewal of the marketing authorisation.                                                                                                                                                                                                      | 31/01/2019 | 02/04/2019 | SmPC, Annex II and PL | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Deltyba, subject to the modified Specific Obligations and Conditions as laid down in Annex II to the opinion. Minor amendments to the product information are introduced, pertaining the correct denotation for tenofovir disoproxil', (245 mg daily) (SmPC section 4.5) and adding |

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |     | of antimalarials with QT-prolonging potential, to be listed in 'special considerations - cardiac risk factors' (SmPC section 4.4. and PL).   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0035/G         | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch | 13/02/2019 | n/a |                                                                                                                                              |
| PSUSA/10213 /201804 | Periodic Safety Update EU Single assessment - delamanid                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 29/11/2018 | n/a | PRAC Recommendation - maintenance                                                                                                            |
| II/0030             | Update of the RMP (finally approved version 2.11), as requested by PRAC following the assessment of the Annual renewal to revise the risk re- categorisation justifications and lay language wording, as well as to add clarifications to the described additional pharmacovigilance activities to assess the effectiveness of risk minimisation measures and the set up date of an EU network of                                                                                                                                                                                | 06/09/2018 | n/a |                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

|                     | laboratories. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required   |            |            |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0031           | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                         | 11/06/2018 | 02/04/2019 | Annex II and PL       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| PSUSA/10213 /201710 | Periodic Safety Update EU Single assessment - delamanid                                                                                                                                                                                                                                                        | 17/05/2018 | n/a        |                       | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| II/0021             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                              | 17/05/2018 | 02/04/2019 | SmPC, Annex II and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| R/0027              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                        | 22/02/2018 | 19/04/2018 | Annex II              | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Deltyba, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. |

<div style=\"page-break-after: always\"></div>

| N/0029              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                              | 17/04/2018   | 02/04/2019   | PL                     |                                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|-----------------------------------|
| PSUSA/10213 /201704 | Periodic Safety Update EU Single assessment - delamanid                                                                                                                                                                                                                                                                                                                                                                                                                                       | 30/11/2017   | n/a          |                        | PRAC Recommendation - maintenance |
| IB/0026             | B.II.f.1.e - Stability of FP - Change to an approved stability protocol                                                                                                                                                                                                                                                                                                                                                                                                                       | 09/10/2017   | n/a          |                        |                                   |
| IA/0025/G           | This was an application for a group of variations. B.II.e.1.b.3 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Deletion of an immediate packaging container without a complete deletion of a strength or pharmaceutical form B.II.e.5.b - Change in pack size of the finished product - Deletion of a pack size(s)                                                                                                                    | 26/09/2017   | 19/04/2018   | SmPC, Labelling and PL |                                   |
| II/0020/G           | This was an application for a group of variations. B.I.a.2.b - Changes in the manufacturing process of the AS - Substantial change to the manufacturing process of the AS which may have a significant impact on the quality, safety or efficacy of the medicinal product B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) | 14/09/2017   | n/a          |                        |                                   |

<div style=\"page-break-after: always\"></div>

|                     | and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate   |            |            |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0023             | B.II.d.1.d - Change in the specification parameters and/or limits of the finished product - Deletion of a non-significant specification parameter                                                                                                                                                                                                                               | 26/07/2017 | n/a        |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| IB/0022             | B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                            | 26/07/2017 | n/a        |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| PSUSA/10213 /201610 | Periodic Safety Update EU Single assessment - delamanid                                                                                                                                                                                                                                                                                                                         | 05/05/2017 | n/a        |          | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| N/0019              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                | 04/05/2017 | 19/04/2018 | PL       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| R/0017              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                         | 26/01/2017 | 03/03/2017 | Annex II | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Deltyba, subject to the Specific Obligations and Conditions as laid down in Annex II |

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |            |                    | to the Opinion.                                                                                                |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|--------------------|----------------------------------------------------------------------------------------------------------------|
| PSUSA/10213 /201604 | Periodic Safety Update EU Single assessment - delamanid                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 01/12/2016 | n/a        |                    | PRAC Recommendation - maintenance                                                                              |
| II/0014             | Update of section 5.1 of the SmPC further to the submission of final clinical study report for trial 242- 12-244 'Determination of Delamanid MIC Values and Sub-species Analysis of Mycobacterium tuberculosis Complex Isolates'. Moreover the MAH has taken the occasion to implement version 10.0 of the QRD template. The date of the latest renewal has been included as well. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority | 06/10/2016 | 03/03/2017 | SmPC and Labelling | The statement that a clinical breakpoint for delamanid has not been determined has been removed from the SmPC. |
| IAIN/0016           | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                               | 05/10/2016 | n/a        |                    |                                                                                                                |
| IB/0013/G           | This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF                                                                                                                                                                                                                                              | 07/06/2016 | n/a        |                    |                                                                                                                |
| PSUSA/10213         | Periodic Safety Update EU Single assessment -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 13/05/2016 | n/a        |                    | PRAC Recommendation - maintenance                                                                              |

<div style=\"page-break-after: always\"></div>

| /201510             | delamanid                                                                                                                                                                                                                                         |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0010              | Renewal of the marketing authorisation.                                                                                                                                                                                                           | 28/01/2016 | 11/03/2016 |             | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Deltyba, subject to the Specific Obligations and Conditions as laid down in Annex II of the Marketing Authorisation. |
| N/0012              | Inclusion of the list of the local representatives at the end of the package leaflet. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                            | 04/03/2016 | 03/03/2017 | PL          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| PSUSA/10213 /201504 | Periodic Safety Update EU Single assessment - delamanid                                                                                                                                                                                           | 06/11/2015 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| IA/0009             | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                  | 16/09/2015 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| IB/0007/G           | This was an application for a group of variations. 1) B.I.d.1 a.4 (Type IB) - to increase the retest period of the active substance from 48 months to 60 months when stored below 30C. 2) B.II.f.1 b.1 (Type IB) - to increase the shelf-life of | 03/06/2015 | 11/03/2016 | SmPC and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|                     | the finished product packaged in glass bottles and aluminum/aluminum foil blisters from 4 years to 5 years (section 6.3 of the SmPC is updated). In addition the MAH took the opportunity to add the date of the latest renewal in the SmPC, to correct a typographical error in the SmPC (for all languages), and to correct a typographical error in the Latvian version of the package leaflet. Moreover, a typographical error has been corrected in Modules 2.3.P.2, 2.3.P.3, 3.2.P.2.3, 3.2.P.3.3, 3.2.P.3.4. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale   |            |     |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| II/0006             | Submission of final study report for Trial 242-13-246 'A Phase 1 Trial to Assess the Mass Balance and Pharmacokinetics of 14C-OPC-67683 Following Oral Administration in Healthy Subjects' C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 21/05/2015 | n/a |                                   |
| PSUSA/10213 /201410 | Periodic Safety Update EU Single assessment - delamanid                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 07/05/2015 | n/a | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| R/0004      | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 26/02/2015   | 24/04/2015   |                        | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Deltyba, subject to the Specific Obligations and Conditions as laid down in Annex II to the Opinion.   |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0002/G   | This was an application for a group of variations. B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data) B.I.d.1.z - Stability of AS - Change in the re-test period/storage period or storage conditions - Other | 06/08/2014   | 24/04/2015   | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| IAIN/0003   | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                                                                                                                          | 17/07/2014   | n/a          |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| IAIN/0001/G | This was an application for a group of variations. A.5.a - To change the name of the site responsible for primary packaging, secondary packaging, import                                                                                                                                                                                                                                                                                                                                                 | 12/06/2014   | 24/04/2015   | Annex II and PL        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| and batch release of the finished product. The address remains unchanged. B.II.b.2.c.1 - To add an alternative site responsible for importation and batch release of the finished product. In addition, the applicant took the opportunity to amend product information and labelling with editorial changes. A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|